Wed, Dec 17, 2014, 6:48 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Array BioPharma, Inc. Message Board

  • merrimack71 merrimack71 Oct 11, 2013 1:02 PM Flag

    Cramer: I'd sell these stocks

    Like I said, it took BALLS to embarrass Cramer like this. Biotech is out, because they messed with the man. How come this Goddess is ALWAYS RIGHT?

    Cramer had advocated long positions in these stocks for quite some time. But no more.
    "After having some incredible runs this year, I think it's time to ring the register on pretty much any biotech that's smaller than $10 billion," Cramer said.
    That includes but is not limited to Insys Therapeutics up 459% for the year, Acadia Pharma (ACAD) up 390%, Celldex (CLDX) up 323% ytd, NPS Pharma , up 263%,Isis Pharma (ISIS) up 219% and Tesaro up 124%.
    "The same goes for all of the other small-cap biotechs that are up huge for the year," Cramer said.
    Considering the gains, Cramer thinks it would be irresponsible not to take at least some money off the table. In this sector, he feels it's especially prudent given smaller biotechs are often nothing more than bets on FDA approval.
    That was the case with Ariad, said Cramer. "Earlier this week, the FDA halted enrollment in clinical trials of Ariad's main drug candidate because it seemed to be causing blood clots. As a result, Ariad lost 66% of its value in a single day."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • burnaka Oct 12, 2013 7:00 PM Flag

      Glad Cramer.s call has no bearing on Arry, but he did give a nice shopping list of high flyers some of which have a small pipeline, like insy, tsro, have a quarter of what Arry has in theirs. Just because Cramer made the call the damage is usually 3-4 days as his horde has little staying power and moves on to his next chirp.

      Looking over that list, and their respective pipelines, ISIS by FAR has the strongest stable of drug candidates with 4 phase 3 drugs and 16 phase 2 drugs, Arry has half that, and uses the same partnering model. Currently array trades at 1/5 the value of isis. What makes ISIS compelling is their drugs target a large variety of indications, cardio, rare disease, metabolic, cancer, inflammation, etc. If I had to pick one from the list it would be ISIS for a long term hold, 3-4 years, if I had to pick two, the second, not on the list would be Arry tied for second with OPK.

4.71+0.120(+2.61%)Dec 17 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.